Nurix Therapeutics. has been granted a patent for combination therapies involving Cbl-b inhibitor compounds. The patent includes methods for treating colon, colorectal, and breast cancers using specific dosages of these compounds, along with related compositions and kits. GlobalData’s report on Nurix Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Nurix Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. Nurix Therapeutics's grant share as of June 2024 was 8%. Grant share is based on the ratio of number of grants to total number of patents.
Combination therapies using cbl-b inhibitors for cancer treatment
The granted patent (Publication Number: US12016860B2) outlines a method for treating colon cancer, colorectal cancer, or breast cancer in patients who require such intervention. The treatment involves the administration of a Cbl-b inhibitor compound, with dosages ranging from 0.1 mg to 50 mg. This method aims to enhance therapeutic outcomes for patients suffering from these specific types of cancer by utilizing the properties of the Cbl-b inhibitor.
Additionally, the patent specifies the use of anti-PD1 antibodies in conjunction with the Cbl-b inhibitor. It identifies three particular anti-PD1 antibodies that can be employed in the treatment regimen: Pembrolizumab, nivolumab, and cemiplimab. This combination approach may provide a synergistic effect, potentially improving the efficacy of cancer treatment in the specified patient population.
To know more about GlobalData’s detailed insights on Nurix Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
